Athens, 29 July 2021- Karatzas & Partners advised on the sale of a leading European pharmaceutical and drug delivery technology company, to global private markets firm (acting on behalf of its clients). The transaction values the business at c. €1.6 billion. 

The transaction is one of the largest ever in terms of selling value in the Greek market and is subject to the receipt of customary regulatory approvals, which are expected within 2021.